Bio-Rad Laboratories has launched its newest cardiac control product, Cardiac Advance. Designed to monitor the precision of instrument testing for cardiac events, this next generation control is optimized with Troponin I and T targets near the limit of instrument detection adhering to the latest guidelines set by AACC and IFCC. In addition, Cardiac Advance control is consolidated with 10 of the most tested cardiac analytes including Troponin, CK-MB, BNP/ProBNP, and Myoglobin. 

Each year, an estimated 17.9 million people lose their lives to Cardiovascular Disease (CVD). This accounts for nearly 32% of all deaths globally, making CVD the world’s leading cause of death. Of these, 85% are due to heart attack and stroke with half of the victims dying before they reach the hospital, according to the World Health Organization. 

When a patient experiences chest pain, critical treatment decisions require timely detection and diagnosis. In turn, diagnosis often relies on an accurate assessment of the correct cardiac markers, which carry significant importance for both patient and care provider in determining the correct course of treatment.  

Because so much is at stake, a one-size-fits-all control may not sufficiently monitor performance where the laboratory needs it most. This makes it critical for laboratories to choose quality control products targeted at medical decision levels appropriate for the cardiac markers tested.  

Bio-Rad’s Cardiac Advance control is available in multiple formats including the standard Liquichek human serum-based control as well as automation ready InteliQ and compact vial configurations designed to help streamline QC workflows to save time and resources.  

Cardiac Advance controls are compatible with Siemens and Roche platforms and are available in the US, Europe, and select Asian markets.  

For more information on Cardiac Advance controls visit